A Disintegrin And Metalloprotease 17 (ADAM17) Antibody (PE)

Product specifications

Primary Antibodies

A Disintegrin And Metalloprotease 17 (ADAM17)

Mouse

Human

FCM: 1-5 µl/106 cells. Optimal dilutions/concentrations should be determined by the end user.

Monoclonal

PE

IgG

Purified by Protein A and Protein G affinity chromatography.

100 tests

200 tests

500 tests

Liquid

FCM

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Please enquire.

Aliquot and store at 2°C to 8°C upon receipt. Avoid exposure to light.

No

CSVP, CD156B, TACE,TNF-Alpha Convertase,TNF-Alpha Converting enzyme,adam-17

Antibody anti-ADAM17

RUO

Descripción

ADAM17, also known as ADAM metallopeptidase domain 17 or tumor necrosis factor-alpha converting enzyme (TACE), is a member of the ADAM family of proteins. Like other ADAM proteins, it possesses a complex domain structure with distinct functional regions, including a metalloproteinase domain responsible for its proteolytic activity.ADAM17 is a transmembrane protein. Consists of several domains, including a metalloproteinase domain, a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and a cytoplasmic tail. Is responsible for the cleavage and release of various membrane-bound proteins, including cytokines, growth factors, receptors, and adhesion molecules. One of its most well-known substrates is tumor necrosis factor-alpha (TNF-α).ADAM17 cleaves the membrane-bound precursor form of TNF-α to release its soluble form into the extracellular space. Soluble TNF-α can then bind to its receptors on target cells, initiating signaling cascades involved in inflammation, apoptosis, and immune responses.ADAM17 also sheds and regulates the activity of other important proteins, including epidermal growth factor receptor (EGFR) ligands, transforming growth factor-alpha (TGF-α), and Notch receptor. Dysregulation of ADAM17 activity has been implicated in various diseases, including inflammatory disorders, autoimmune diseases, cancer, and cardiovascular diseases. In particular, increased ADAM17 activity and elevated levels of its substrates, such as TNF-α, have been observed in conditions like rheumatoid arthritis, inflammatory bowel disease, and certain cancers. Given its central role in inflammation and disease pathogenesis, ADAM17 is considered a promising therapeutic target

Related Products

Human ADAM17(Disintegrin and metalloproteinase domain-containing protein 17) ELISA Kit

Ver Producto

Mouse adam17 (Disintegrin and metalloproteinase domain-containing protein 17) ELISA Kit

Ver Producto

anti- ADAM17 antibody

This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biologic processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The encoded preproprotein is proteolytically processed to generate the mature protease. The encoded protease functions in the ectodomain shedding of tumor necrosis factor-alpha, in which soluble tumor necrosis factor-alpha is released from the membrane-bound precursor. This protease also functions in the processing of numerous other substrates, including cell adhesion proteins, cytokine and growth factor receptors and epidermal growth factor (EGF) receptor ligands. The encoded protein also plays a prominent role in the activation of the Notch signaling pathway. Elevated expression of this gene has been observed in specific cell types derived from psoriasis, rheumatoid arthritis, multiple sclerosis and Crohn's disease patients, suggesting that the encoded protein may play a role in autoimmune disease.

Ver Producto